Abstract: The present disclosure provides compositions and methods that employ the compositions for conducting pairwise sequencing and for generating concatemer template molecules for pairwise sequencing. The concatemers can be generated using a rolling circle amplification reaction which is conducted either on-support, or conducted in-solution and then distributed onto a support. The rolling circle amplification reaction generates concatemers containing tandem copies of a sequence of interest and at least one universal adaptor sequence. An increase in the number of tandem copies in a given concatemer increases the number of sites along the concatemer for hybridizing to multiple sequencing primers which serve as multiple initiation sites for polymerase-catalyzed sequencing reactions. When the sequencing reaction employs detectably labeled nucleotides and/or detectably labeled multivalent molecules (e.g.
Type:
Grant
Filed:
July 15, 2021
Date of Patent:
December 27, 2022
Assignee:
Element Biosciences, Inc.
Inventors:
Sinan Arslan, Junhua Zhao, Molly He, Samantha Snow, William Light, Matthew Kellinger, Michael Previte, Michael Kim, Hua Yu, Yu-Hsien Hwang-Fu, Marco Tjioe, Andrew Boddicker
Abstract: Embodiments of the present disclosure provide dual pore sensors and methods for producing these dual pore sensors. The method includes forming a film stack, where the film stack contains two silicon layers and two membrane layers, and then etching the film stack to produce a channel extending therethrough and having two reservoirs and two nanopores. The method also includes depositing a oxide layer on inner surfaces of the reservoirs and nanopores, depositing a dielectric layer on the oxide layer, and forming a metal contact extending through a portion of the stack. The method further includes etching the dielectric layers to form wells, etching the first silicon layer to reveal the protective oxide layer deposited on the inner surfaces of a reservoir, and etching the protective oxide layer deposited on the inner surfaces of the reservoirs and the nanopores.
Type:
Grant
Filed:
January 9, 2020
Date of Patent:
December 27, 2022
Assignee:
APPLIED MATERIALS, INC.
Inventors:
Mark J. Saly, Keenan Navarre Woods, Joseph R. Johnson, Bhaskar Jyoti Bhuyan, William J. Durand, Michael Chudzik, Raghav Sreenivasan, Roger Quon
Abstract: The present disclosure relates to a vaginal system that prevents pregnancy comprised of segesterone acetate and ethinyl estradiol and is configured for thirteen 28-day product-use cycles.
Abstract: A magnetic particle is disclosed. The magnetic particle comprises a magnetic material having a maximum field strength in a range of from about 20 emu/g to about 250 emu/g and a remanence in a range of from about 0 emu/g to about 30 emu/g. The magnetic particle further comprises an outer surface containing a ligand. The ligand interacts with an analyte of interest in the sample solution.
Type:
Grant
Filed:
January 15, 2021
Date of Patent:
December 20, 2022
Assignee:
Beckman Coulter, Isse.
Inventors:
Jeffrey J. Corpstein, Evan Farthing, Thomas G. Keen, Jianli Zhao, Asmita Patel, Yuandan Liu, Cuong N. Hoang, Emmet Welch
Abstract: The invention provides a method of treatment comprising reducing therapy-induced adverse effects (TIAE), including chemotherapy-induced adverse effects (CIAE), such as chemotherapy-induced peripheral neuropathy (CIPN) and/or chemotherapy-induced cardiovascular adverse effects (CICAE) in a subject being treated with a CIAE-inducing anti-cancer active ingredient by co-administering to the subject a pharmaceutically effective amount of a NCS-1-protective composition. Related pharmaceutical compositions, diagnostics and screening techniques are also provided.
Type:
Grant
Filed:
June 2, 2017
Date of Patent:
December 6, 2022
Assignee:
YALE UNIVERSITY
Inventors:
Barbara Ehrlich, Sara Rockwell, Jennifer Benbow
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
Type:
Grant
Filed:
December 23, 2021
Date of Patent:
December 6, 2022
Assignees:
BioXcel Therapeutics, Inc., ARx, LLC
Inventors:
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Abstract: Sequencing-by-synthesis (SBS) method is provided that includes providing a detection apparatus that includes an array of magnetically-responsive sensors. Each of the magnetically-responsive sensors is located proximate to a respective designated space to detect a magnetic property therefrom. The detection apparatus also includes a plurality of nucleic acid template strands located within corresponding designated spaces. The method also includes conducting a plurality of SBS events to grow a complementary strand by incorporating nucleotides along each template strand. At least some of the nucleotides are attached to corresponding magnetic particles having respective magnetic properties. Each of the plurality of SBS events includes detecting changes in electrical resistance at the magnetically-responsive sensors caused by the respective magnetic properties of the magnetic particles.
Abstract: A method of manipulating microdroplets having an average volume in the range 0.5 femtolitres to 10 nanolitres comprised of at least one biological component and a first aqueous medium having a water activity of aw1 of less than 1 is provided. It is characterised by the step of maintaining the microdroplets in a water-immiscible carrier fluid which further includes secondary droplets having an average volume less than 25% of the average volume of the microdroplets up to and including a maximum of 4 femtolitres and wherein the volume ratio of carrier fluid to total volume of microdroplets per unit volume of the total is greater than 2:1. The method may be employed for example with microdroplets containing biological cells or with microdroplets containing single nucleoside phosphate such as are prepared in a droplet-based nucleic acid sequencer.
Type:
Grant
Filed:
February 7, 2020
Date of Patent:
November 22, 2022
Assignee:
LIGHTCAST DISCOVERY LTD
Inventors:
Tom Isaac, Barnaby Balmforth, Jasmin Conterio, Kerr Francis Johnson, Maciej Sosna, Richard Ingham, Gareth Podd
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
Type:
Grant
Filed:
December 23, 2021
Date of Patent:
November 15, 2022
Assignees:
BioXcel Therapeutics, Inc., ARx, LLC
Inventors:
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Abstract: The present invention provides compositions (such as pharmaceutical compositions), and commercial batches of such compositions, comprising nanoparticles comprising albumin and rapamycin. The compositions (such as pharmaceutical compositions) have specific physicochemical characteristics and are particularly suitable for use in treating diseases such as cancer. Also provided are methods of making and methods of using the compositions (such as pharmaceutical compositions).
Abstract: Disclosed herein are methods and compositions for determining an improved estimate of the fractional abundance of target analytes (e.g., specific polynucleotide sequences) in a sample using a nanopore sensor having one or more nanopores-, e.g., by correcting errors inherent to identifying and correlating electrical signals to amounts of a target analyte or reference analyte in a sample.
Type:
Grant
Filed:
April 22, 2019
Date of Patent:
November 1, 2022
Assignee:
Ontera Inc.
Inventors:
Yanan Zhao, William McKenna, William B. Dunbar
Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
Type:
Grant
Filed:
July 17, 2020
Date of Patent:
October 25, 2022
Assignees:
BioXcel Therapeutics, Inc., ARx, LLC
Inventors:
Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
Abstract: Corona Phase Molecular Recognition (CoPhMoRe) utilizing a heteropolymer adsorbed onto and templated by a nanoparticle surface to recognize a specific target analyte can be used for macromolecular analytes, including proteins. A variant of a CoPhMoRe screening procedure of single walled carbon nanotubes (SWCNT) can be used against a panel of human blood proteins, revealing a specific corona phase that recognizes fibrinogen and insulin, respectively, with high selectivity.
Type:
Grant
Filed:
November 22, 2016
Date of Patent:
October 18, 2022
Assignee:
Massachusetts Institute of Technology
Inventors:
Michael S. Strano, Gili H. Bisker Raviv
Abstract: A sample analyzing method includes: denaturing DNA by heating a measurement specimen; bleaching the measurement specimen to inhibit autofluorescence from the measurement specimen; binding a fluorescent dye to a test substance in the measurement specimen; and capturing an image of fluorescence originated from the fluorescent dye by irradiating the measurement specimen with light. The DNA denaturation treatment is performed before the bleaching.
Abstract: The present invention relates to topical pharmaceutical emulsion compositions comprising a therapeutically effective amount of 3,5-Dihydroxy-4-isopropyl-trans-stilbene or a pharmaceutically acceptable salt thereof, an oil phase, a water phase, a surfactant, and an antioxidant, and wherein the emulsion composition is homogeneous and/or the active is solubilized in the oil phase. The invention also relates to methods of treating a dermatological condition or disorder in a patient by administering the present compositions to the skin of the patient.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
October 4, 2022
Assignee:
DERMAVANT SCIENCES GMBH
Inventors:
Sujatha D. Sonti, Joey Roger Thomas, Jon Lenn, Leandro Santos, Justin Whiteman, Michael Quinn Doherty, Mary Bedard, Piyush Jain
Abstract: A therapeutic composition comprising a purified fraction of adipose-derived mesenchymal stem cells encapsulated in a three-dimensional biocompatible gel matrix, and methods, and systems for preparing and using encapsulated adipose-derived mesenchymal stem cells. Hydrogel microbeads encapsulating stem cells maintain the viability and location of the stem cells for an extended period as compared to stem cells in suspension. The gel matrix allows the release of cellular factors from the encapsulated stem cells to surrounding tissues to achieve desired therapeutic results.
Abstract: The disclosure provides three-dimensional crosslinked polymer networks comprising one or more channels extending from the surface and/or near the surface of the network into the interior of the network, arrays comprising the networks, processes for making the networks, and uses of the networks and arrays.
Abstract: The subject invention provides materials and methods for single-step fluorescence and electrochemical detection of small molecules, e.g., fentanyl and its analogs, in a sample. The subjection invention provides nucleic acids materials, e.g., aptamers (nucleic acid oligonucleotides) that can bind to fentanyl and its analogs with nanomolar affinity and high specificity against illicit drugs, adulterants, and cutting agents commonly existing in seized samples. The method for detecting fentanyl and/or its analogs in a sample comprises contacting the sample with an aptamer-based sensor selective for fentanyl and its analogs, and sensitively, specifically, and rapidly detecting fentanyl and/or its analogs in the sample.
Type:
Grant
Filed:
June 22, 2021
Date of Patent:
August 9, 2022
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: A variety of nanoparticles or microparticles may be used to treat diseases such as restenosis or blood clots. For example, a nanoparticle or microparticle may include a core having a biodegradable polymer, an exterior having hydrophilic moieties. and a therapeutic agent. The nanoparticles may include targeting moieties that target the nanoparticle or microparticle to an arterial lesion. The nanoparticle or microparticle may include an exterior shell around the core to increase stability of the nanoparticle or microparticle. The nanoparticle or microparticle may include a magnetic particle to allow targeted delivery of the nanoparticle or microparticle via a magnetic field. The nanoparticles or microparticles may be coated on a medical device, such as a catheter balloon or a stent, or may be delivered systemically or locally to patients in need thereof.